Navigation Links
Eye Disease Continuing to Increase Among Americans
Date:4/2/2008

Latest Data Shows Number of Eye Disease Patients Rising

CHICAGO, April 2 /PRNewswire/ -- Millions of Americans are currently living with age-related eye disease and, according to the latest research from Prevent Blindness America and the National Eye Institute, that number is continuing to climb. With more than 130 million Americans aged 40 and older, more than 30 million suffer from leading causes of vision loss such as cataract, diabetic retinopathy, macular degeneration and glaucoma, according to the newly revised edition of the "Vision Problems in the U.S." study.

The study was an updating of the data from the 2002 Vision Problems in the U.S. report on the prevalence of eye diseases and conditions in America. Information gathered was the result of data collection from a systematic review of the major epidemiological studies from leading ophthalmologic epidemiologists.

Revised data from the Vision Problems in the U.S. study showed that among Americans aged 40 and older:

-- Age-related macular degeneration (AMD) cases rose 25 percent, the

largest increase of the major eye diseases. Currently, 2 million

Americans have been diagnosed with AMD.

-- Diabetic retinopathy affects more than 4.4 million. As the diabetes

epidemic rages on, the number of cases of the disease will continue to

soar.

-- There are 2.29 million American adults with glaucoma, the sneak thief

of sight. Yet 2 million more are estimated to have the disease and do

not know it.

-- Cataract is the leading cause of blindness in the world and

22.3 million American adults have the disease. Although surgery can

be highly successful, not all Americans are fortunate enough to have

access to affordable care.

"Our research shows that vision loss continues to threaten the quality of life for millions of Americans," said Daniel D. Garrett, senio
'/>"/>

SOURCE Prevent Blindness America
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Huge virulence gene superfamily responsible for devastating plant diseases
2. Mayo Clinic Identifies Infection Risks for Patients with Inflammatory Bowel Disease
3. Symposium to explore role nanoparticles may play in disease
4. Smokers with lung disease need more than brief intervention
5. Researchers identify a gene responsible for cases of Lou Gehrigs disease
6. Researchers identify a gene responsible for Lou Gehrigs disease
7. Scientists: New technique identifies molecular biomarkers for disease
8. Jiffy Lube(R) Raises $1 Million for American Heart Associations Go Red For Women(TM) Movement to Fight Heart Disease
9. Study finds support for PCI in unprotected left main disease
10. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
11. Decreased sexual satisfaction is not associated with cardiovascular disease in postmenopausal women
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 1Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 2Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 3Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 4Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 1Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 2Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 3Osseon Receives CE Mark 57784 1Osseon Receives CE Mark 57784 2